



## Artificial Intelligence in Cancer Screening

Guest Editors:

**Prof. Dr. Mario Mascalchi**

Department of Experimental and  
Clinical Biomedical Sciences  
“Mario Serio”, University of  
Florence, 50121 Florence, Italy

**Dr. Stefano Diciotti**

Department of Electrical,  
Electronic, and Information  
Engineering “Guglielmo  
Marconi”—DEI, University of  
Bologna, Bologna, Italy

Deadline for manuscript  
submissions:

**31 October 2024**

### Message from the Guest Editors

Artificial intelligence (AI) is a powerful class of methods for decision support, having rapidly evolved over recent years. Several approaches have been developed to analyze the increasingly extensive and variably complex datasets often publicly available. With enthusiasm, AI is beginning to be applied to several facets of screening intervention, from the risk stratification of subjects to be invited, to the reading of radiological, optical, and histo-cytopathological images, and integration with stool, serum, and fluid biomarkers to ultimately promote and reinforce the implementation of screening in public health services, thanks to an improved cost/benefit ratio.

In this Special Issue of *Cancers*, we offer an overview of the current and potential applications of AI to the screening interventions considering, on the one hand, the AI methodological and technical developments and, on the other hand, the applications to specific screening contexts.

- artificial intelligence
- biomarkers
- breast cancer
- cancer screening
- cervical cancer
- colorectal cancer
- deep learning
- lung cancer
- machine learning
- risk stratification





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)